This webinar will examine the role of modern weight loss medications, Semaglutide and Tirzepatide, in managing obesity and type 2 diabetes.
Expert speaker, Dr Matthew Procter, will explore how these medications impact the lifestyle factors that contribute to diabetes and obesity and discuss whether medication could lower rates of these conditions and reduce morbidity and mortality in insured populations. Dr Procter will also address strategies for risk assessment in applicants using these medications.
Key Takeaways
- Explain the mechanism of action of modern weight loss medications and their potential side effects
- Understand the indications, and role these medications play, in managing patients with obesity and/or type two diabetes mellitus
- Discuss an underwriting approach to life insurance applicants who use these medications, considering the long term morbidity and mortality risks of obesity and diabetes mellitus.
Speakers
Dr Matthew Procter, Hall, Chief Medical Officer and Head of Medical Services, Hannover Re